AG
ITOS

Algert Global’s iTeos Therapeutics ITOS Stock Holding History

Algert Global’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-74,477
Closed -$743K – 1236
2025
Q2 		$743K Sell
74,477
-5,475
-7% -$44.1K 0.02% 862
2025
Q1 		$477K Buy
79,952
+10,440
+15% +$76.7K 0.01% 927
2024
Q4 		$534K Sell
69,512
-186,627
-73% -$1.6M 0.01% 894
2024
Q3 		$2.62M Buy
256,139
+122,730
+92% +$1.87M 0.07% 467
2024
Q2 		$1.98M Buy
133,409
+6,139
+5% +$88K 0.07% 467
2024
Q1 		$1.74M Sell
127,270
-1,590
-1% -$17.3K 0.07% 458
2023
Q4 		$1.41M Buy
128,860
+32,680
+34% +$324K 0.06% 526
2023
Q3 		$1.05M Buy
96,180
+54,590
+131% +$698K 0.05% 558
2023
Q2 		$551K Buy
+41,590
New +$593K 0.02% 794
2022
Q2 		– Sell
-11,907
Closed -$383K – 1296
2022
Q1 		$383K Buy
+11,907
New +$433K 0.03% 896

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Algert Global's ITOS Position: Q3 2025 in Review

Algert Global sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 74,477 shares — an estimated $743K sold.

Algert Global first reported a position in ITOS in Q1 2022 and held it in 10 quarters. The position peaked at $2.62M in Q3 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Algert Global reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 74,477 iTeos Therapeutics shares in Q3 2025, an estimated $743K.
  • Algert Global first reported a position in iTeos Therapeutics in Q1 2022 and held it in 10 quarters.
  • Algert Global's iTeos Therapeutics position peaked at $2.62M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.